^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lymphir (denileukin diftitox-cxdl)

    i
    Company:
    Citius Oncology, Eisai
    Drug class:
    IL-2 stimulant
    Related drugs:
    Apply
    T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors (NCT05200559)
    Phase 1/2
    Haider Mahdi
    Recruiting
    Last update posted :
    11/09/2023
    Initiation :
    09/30/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    MSI • CD4 • IL2
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lymphir (denileukin diftitox-cxdl)
    Study of E7777 Prior to Kymriah for R/R DLBCL (NCT04855253)
    Phase 1/2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    06/09/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    MYC
    |
    MYC expression
    |
    Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
    A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma (NCT01871727)
    Phase 3
    Eisai Inc.
    Completed
    Last update posted :
    12/12/2022
    Initiation :
    05/30/2013
    Primary completion :
    12/06/2021
    Completion :
    12/14/2021
    IL2RA • IL2 • ISG20
    |
    Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)
    Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma (NCT02676778)
    Phase 2
    Eisai Co., Ltd.
    Completed
    Last update posted :
    07/15/2021
    Initiation :
    03/28/2016
    Primary completion :
    04/26/2019
    Completion :
    04/26/2019
    IL2
    |
    Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)